Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yamani-15/5 in severe calcific PAD
NCT02539303Phase 1Withdrawn
- Sponsor
- Mayo Clinic
- Start
- Aug 2015
- Primary completion
- Aug 2022
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of henna in Peripheral Arterial Disease (PAD), sponsored by Mayo Clinic. Primary endpoint: Feasibility. Planned start Aug 2015; status: withdrawn.
02
Drugs
henna
03
Conditions
Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT02539303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02539303.